SCHEMBL20607103

SCHEMBL20607103

COC(=O)CC(C)C(=O)c1ccc(OC)c(Cl)c1F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
TNF P01375 2/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.35
GLA P06280 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
LMNA P02545 1/20 0.35
CLCN2 P51788 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29628757 1.00 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL20607275 0.85 PDE4D (0.42) PDE4DTNFALDH1A1MAPTRAB9A
SCHEMBL29628796 0.85 PDE4A (0.40) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL29628654 0.85 PDE4D (0.42) PDE4DTNFALDH1A1MAPTRAB9A
SCHEMBL20607466 0.85 PDE4A (0.40) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL20607313 0.84 PDE4A (0.40) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL29628815 0.84 PDE4A (0.40) PDE4DPDE4APDE4BPDE4CTNF
SCHEMBL20607475 0.83 P2RX7 (0.32) PDE4DPDE4APDE4BPDE4C
SCHEMBL29628743 0.83 P2RX7 (0.32) PDE4DPDE4APDE4BPDE4C
SCHEMBL20607238 0.78 SCN9A (0.35) PDE4DPDE4APDE4BPDE4CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400520-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-05 US disclosed
CN-108779076-B 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives 大塚制药株式会社 2022-05-03 CN disclosed
EP-3423440-B9 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS OTSUKA PHARMA CO LTD (JP) 2021-07-28 EP disclosed
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-06-10 US disclosed
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-06-10 US disclosed
EP-3423440-B1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS OTSUKA PHARMA CO LTD (JP) 2021-01-06 EP disclosed
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-11 US disclosed
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-11 US disclosed
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-07 US disclosed
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-07 US disclosed
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
EP-3423440-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE Otsuka Pharmaceutical Co., Ltd. (JP) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 PDE4D 2912/4885PDE4A 3094/4885PDE4B 2646/4885
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 PDE4D 2912/4885PDE4A 3094/4885PDE4B 2646/4885
US-20240400520-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 PDE4D 2912/4885PDE4A 3094/4885PDE4B 2646/4885
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 PDE4D 2912/4885PDE4A 3094/4885PDE4B 2646/4885
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative VHL, H1-5, PRMT5 PDE4D 2912/4885PDE4A 3094/4885PDE4B 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.